Țară: Irlanda
Limbă: engleză
Sursă: HPRA (Health Products Regulatory Authority)
TIMOLOL MALEATE
Wockhardt UK Limited
S01ED; S01ED01
TIMOLOL MALEATE
0.25 percent weight/volume
Eye drops, solution
Product subject to prescription which may be renewed (B)
Beta blocking agents1); timolol
Not marketed
2010-12-10
PACKAGE LEAFLET: INFORMATION FOR THE USER TIMOLOL 0.25% W/V EYE DROPS, SOLUTION TIMOLOL 0.5% W/V EYE DROPS, SOLUTION (TIMOLOL MALEATE) (referred to as Timolol Eye Drops in the rest of this leaflet) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET: 1. What Timolol Eye Drops are and what they are used for 2. What you need to know before you use Timolol Eye Drops 3. How to use Timolol Eye Drops 4. Possible side effects 5. How to store Timolol Eye Drops 6. Contents of the pack and other information 1. WHAT TIMOLOL EYE DROPS ARE AND WHAT THEY ARE USED FOR Timolol Eye Drops are available in two strengths: Timolol 0.25% w/v Eye Drops, Solution and Timolol 0.5% w/v Eye Drops, Solution. Timolol Eye Drops is a member of a group of medicines known as beta-blockers and it is used to reduce the pressure inside your eyeball(s) if you have a condition such as high blood pressure that is affecting your eyes, or glaucoma (high pressure in your eyeball), including glaucoma that developed after you had surgery to remove a cataract from your eye(s). 2. WHAT YOU NEED TO KNOW BEFORE YOU USE TIMOLOL EYE DROPS DO NOT USE TIMOLOL EYE DROPS if you are allergic to timolol, beta-blockers such as propranolol (used mainly for high blood pressure) or betaxolol (also used for glaucoma) or any of the other ingredients of this medicine (listed in section 6) if you have now or have had in past respiratory problems such as asthma, severe chronic obstructive bronchitis, (severe lung disease which may cause wheeziness, difficulty in breathin Citiți documentul complet
Health Products Regulatory Authority 01 May 2020 CRN009NNK Page 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Timolol 0.25 % w/v Eye Drops, Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of eye drops contains 2.5 mg of timolol (as 3.4 mg of timolol maleate). Excipient(s) with known effect: Benzalkonium chloride 0.1mg/ml eye drops, solution. 1ml of eye drops contains 16.72 mg of disodium hydrogen phosphate dodecahydrate, equivalent to 4.43 mg of phosphates. 1ml of eye drops contains 3.12 mg of sodium dihydrogen phosphate dehydrate, equivalent to 1.9 mg of phosphates. The total content of phosphates in each 1ml of eye drops is 6.33 mg. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Eye drops, solution. Clear, colourless to light yellow, eye drops solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Timolol is a beta-adrenoreceptor blocking agent used topically in the reduction of elevated intra-ocular pressure in various conditions including the following: patients with ocular hypertension; patients with chronic open-angle glaucoma including aphakic patients; some patients with secondary glaucoma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Recommended therapy is one drop of timolol 0.25% w/v eye drops, solution in the affected eye(s) twice a day. Another strength (timolol 0.5% w/v eye drops, solution) is available. If clinical response is not adequate, dosage may be changed to one drop timolol 0.5% w/v eye drops, solution in each affected eye twice a day. If needed, timolol may be used with other agent(s) for lowering intra-ocular pressure. The use of two topical beta-adrenergic blocking agents is not recommended (see 4.4 'Special warnings and precautions for use'). Intra-ocular pressure should be reassessed approximately four weeks after starting treatment because response to timolol may take a few weeks to stabilise. Provided that the intra-ocular pressure is maintained at satisfactory levels, many patients can then be placed on once-a Citiți documentul complet